IP Library Granted Patent US 12,097,295
Granted Patent B2
US 12,097,295 · App. 17/398,556 · Granted Sep 24, 2024

Packaging solutions

Inventors: Vicki Barniak (Fairport, NY); Catherine Scheuer (West Henrietta, NY); Ruth Julian (Rochester, NY); William T. Reindel (Webster, NY); Erning Xia (Penfield, NY)
Assignee: BAUSCH + LOMB IRELAND LIMITED
A61L12/147B65B55/06B65B55/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,097,295
App. No.
17/398,556
Granted
Sep 24, 2024
Kind
B2
Abstract

A packaging system for the storage of an ophthalmic device is disclosed. The packaging system comprises a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising (a) one or more osmoprotectants, (b) one or more poloxamer comfort agents and (c) one or more polyol demulcents, wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Claims (76)

1. A packaging system for the storage of an ophthalmic device including a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution consisting of:

(a) erythritol;

(b) one or more poloxamer comfort agents;

(c) one or more polyol demulcents;

(d) sodium chloride, potassium chloride or any combination thereof;

(e) a poloxamine;

(f) one or more buffers; and

(g) water;

wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is beat sterilized.

2. The packaging system of claim 1 , wherein the ophthalmic device is a contact lens.

3. The packaging system of claim 1 , wherein the one or more poloxamer comfort agents are one or more copolymers having poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) blocks represented by the structure:

HO(C 2 H 4 O) a (C 3 H 6 O) b (C 2 H 4 O) a H

wherein a is independently at least 1 and b is at least 1.

4. The packaging system of claim 3 , wherein the one or more copolymers have a hydrophilic-lipophilic balance (HLB) ranging from about 5 to about 24.

5. The packaging system of claim 1 , wherein the one or more polyol demulcents is glycerol.

6. The packaging system of claim 1 , wherein the aqueous packaging solution consists of:

about 0.01% to about 10% w/w of erythritol;

about 0.001 wt. % to about 5.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more poloxamer comfort agents; and

about 0.01 to about 10.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more polyol demulcents.

7. The packaging system of claim 1 , wherein the aqueous packaging solution consists of:

0.1% to about 10% w/w of erythritol;

about 0.01 wt. % to about 1.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more poloxamer comfort agents; and

about 0.1 wt. % to about 3.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more polyol demulcents.

8. The packaging system of claim 1 , wherein the aqueous packaging solution consists of:

about 0.01 wt. % to about 5.0 wt. %, based on the total weight of the aqueous packaging solution, of erythritol;

about 0.01 wt. % to about 1.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more poloxamer comfort agents; and

about 0.1 wt. % to about 3.0 wt. %, based on the total weight of the aqueous packaging solution, of glycerol.

9. The packaging system of claim 1 , wherein the sealed container is heat sterilized subsequent to sealing of the container.

10. The packaging system of claim 1 , wherein the aqueous packaging solution consists of:

about 0.01% to about 10% w/w of erythritol;

about 0.001 wt. % to about 5.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more poloxamer comfort agents; and

about 0.01 to about 10.0 wt. %, based on the total weight of the aqueous packaging solution, of glycerol;

0.01 to about 2.5% w/v of the sodium chloride, potassium chloride or any combination thereof; and

about 0.001 to about 5.0 wt. %, based on the total weight of the aqueous packaging solution, of the poloxamine.

11. The packaging system of claim 1 , wherein the one or more buffers are one or more phosphate buffers.

12. The packaging system of claim 1 , wherein the one or more buffers include sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous.

13. A method of preparing a package comprising a storable, sterile ophthalmic device, the method comprising consisting of:

(a) immersing an ophthalmic device in an aqueous packaging solution consisting of:

(i) erythritol,

(ii) one or more poloxamer comfort agents,

(iii) one or more polyol demulcents,

(iv) sodium chloride, potassium chloride or any combination thereof,

(v) a poloxamine,

(vi) one or more buffers, and

(vii) water;

wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg and a pH in the range of about 6 to about 9;

(b) packaging the aqueous packaging solution and the ophthalmic device in a manner preventing contamination of the ophthalmic device by microorganisms; and

(c) sterilizing the packaged aqueous packaging solution and the ophthalmic device.

14. The method of claim 13 , wherein the ophthalmic device is a contact lens.

15. The method of claim 13 , wherein the one or more poloxamer comfort agents are one or more copolymers having poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) blocks represented by the structure:

HO(C 2 H 4 O) a (C 3 H 6 O) b (C 2 H 4 O) a H

wherein a is independently at least 1 and b is at least 1.

16. The method of claim 13 , wherein the aqueous packaging solution consists of:

about 0.01% to about 10% w/w of erythritol;

about 0.001 wt. % to about 5.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more poloxamer comfort agents; and

about 0.1 wt. % to about 3.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more polyol demulcents.

17. The method of claim 13 , wherein the one or more polyol demulcents is glycerol.

18. The method of claim 13 , wherein the aqueous packaging solution consists of:

about 0.01% to about 10% w/w of erythritol;

about 0.001 wt. % to about 5.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more poloxamer comfort agents; and

about 0.01 to about 10.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more polyol demulcents.

19. The method of claim 13 , wherein the aqueous packaging solution consists of:

about 0.1% to about 10% w/w of erythritol;

about 0.01 wt. % to about 1.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more poloxamer comfort agents; and

about 0.1 wt. % to about 3.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more polyol demulcents.

20. The method of claim 13 , wherein the aqueous packaging solution consists of:

about 0.01 wt. % to about 5.0 wt. %, based on the total weight of the aqueous packaging solution, of erythritol;

about 0.01 wt. % to about 1.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more poloxamer comfort agents; and

about 0.1 wt. % to about 3.0 wt. %, based on the total weight of the aqueous packaging solution, of glycerol.

21. The method of claim 13 , wherein the aqueous packaging solution consists of:

about 0.01% to about 10% w/w of erythritol;

about 0.001 wt. % to about 5.0 wt. %, based on the total weight of the aqueous packaging solution, of the one or more poloxamer comfort agents, and

about 0.01 to about 10.0 wt. %, based on the total weight of the aqueous packaging solution, of glycerol;

0.01 to about 2.5% w/v of the sodium chloride, potassium chloride or any combination thereof, and

about 0.001 to about 5.0 wt. %, based on the total weight of the aqueous packaging solution, of the poloxamine.

22. The method of claim 13 , wherein the one or more buffers are one or more phosphate buffers.

Assignments (10)
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (065709/0253) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072460/0691 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY INTEREST Recorded Feb 12, 2024
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 066552/0041 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 29, 2023
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 065709/0253 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 58205/0889) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061874/0717 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 058205/0843) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061778/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2022
From: BARNIAK, VICKI; SCHEUER, CATHERINE; JULIAN, RUTH; REINDEL, WILLIAM T.; XIA, ERNING
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 060974/0986 →
SECURITY INTEREST Recorded Nov 24, 2021
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH+LOMB IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; SOLTA MEDICAL IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 058205/0843 →
SECURITY INTEREST Recorded Nov 24, 2021
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH+LOMB IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 058205/0889 →